  Week 48 efficacy (Part 1)               Proportion of patients with virologic response (95% CI)                           Mean CD4 change from baseline (95% CI)
  --------------------------- ----- ----- --------------------------------------------------------- ----------------------- ----------------------------------------
  Doravirine qd               25    40    73 (56, 85)                                               85 (70, 94)             190 (144, 236)
                              50    43    72 (56, 85)                                               74 (59, 87)             134 (78, 190)
                              100   42    76 (61, 88)                                               86 (72, 95)             155 (117, 194)
                              200   41    83 (68, 93)                                               85 (71, 94)             194 (134, 253)
                              All   166   76 (69, 82)                                               83 (76, 88)             168 (143, 193)
  Efavirenz qhs               600   42    71 (55, 84)                                               79 (63, 90)             179 (127, 230)
  Missing data approach:                                                                            Non-completer=failure   Observed failure

In combination with TDF/FTC.

  Week 48 safety (Part 1)                                            Doravirine (*N*=166)   Efavirenz (*N*=42)
  ------------------------------------------------------------------ ---------------------- --------------------
                                                                     \%                     \%
  One or more clinical AEs                                           88.0                   83.3
  Drug-related (DR) AEs                                              36.7                   57.1
  Serious AE                                                         4.8                    9.5
  Serious and DR AE                                                  0.0                    0.0
  Discontinued due to AE                                             4.2                    4.8
  Discontinued due to DR AE[†](#TF0002_19532){ref-type="table-fn"}   2.4                    4.8
  Discontinued due to serious AE                                     0.6                    0.0

All discontinuations due to DR AE occurred by week 24.
